PDCD1 and lung carcinoma: Given that anti-PD-1/L1 therapy has been successfully applied in the first-line therapy of lung cancer, it is of great interest to validate this observation in clinical patient samples and explore the prognostic value of TET2 expression in predicting the responsiveness of lung cancer patients to anti-PD-1/L1 therapy.